Management of localized prostate cancer by retropubic radical prostatectomy in patients after renal transplantation

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3416-3420

  Hoda, M Raschid ^a   Hamza, Amir ^a   Greco, Francesco ^a   Wagner, Sigrid ^a   Reichelt, Olaf ^a   Heynemann, Hans ^a   Fischer, Kersten ^a   Fornara, Paolo ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

kidney transplantation; prostate cancer; prostate specific antigene; radical prostatectomy

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTATE SPECIFIC ANTIGEN; TACROLIMUS;

ADULT; ARTICLE; BLEEDING; BLOOD LEVEL; BLOOD TRANSFUSION; BONE SCINTISCANNING; CATHETERIZATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; GRAFT REJECTION; HEMATURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LYMPH NODE DISSECTION; LYMPHOCELE; MALE; OPERATION DURATION; PELVIS LYMPH NODE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RECTUM INJURY; RETROSPECTIVE STUDY; SAFETY; TRANSRECTAL ULTRASONOGRAPHY; URETEROPELVIC JUNCTION; URINE INCONTINENCE; WOUND HEALING; WOUND INFECTION;

AGED; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77957229329     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq193     Document Type: Article

References (31)

1. Penn I. Occurrence of cancer in immunosuppressed organ transplant recipients. Clin Transpl 1998; 12: 147-158
2. Kasiske B, Snyder JJ, Gilbertson DT. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
3. Konety BR, Tewari A, Howard RJ et al. Prostate cancer in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery. Urology 1998; 52: 428-432
4. Kleinclauss F, Gigante M, Neuzillet Y et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 2374-2380
5. Elkentaoui H, Robert G, Pasticier G et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology 2010; 75: 126-132
6. Cormier L, Lechevallier E, Barrou B et al. Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation 2003; 75: 237-239
7. Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol 2008; 179: 1349-1352
8. Bayne A, Barry JM, Garzotto M. Radical retropubic prostatectomy after orthotopic liver transplantation. Urology 2005; 65: 175
9. Kleinclauss FM, Neuzillet Y, Tillou X et al. Morbidity of retropubic radical prostatectomy for prostate cancer in renal transplant recipients: multicenter study from Renal Transplantation Committee of French Urological Association. Urology 2008; 72: 1366-1370
10. Hafron J, Fogarty JD, Wiesen A et al. Surgery for localized prostate cancer after renal transplantation. BJU Int 2005; 95: 319-322
11. Walsh PC. Technique of radical retropubic prostatectomy with preservation of sexual function: an anatomic approach. In: DG Skinner, G Lieskovsky (eds). Diagnosis and Management of Genitourinary Cancer. Philadelphia: WB Saunders, 1988; 753-778
12. Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582-1588
13. U.S. Renal Data System. Atlas of End Stage Renal Disease in the United States. Bethesda, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USDRDS 2003 Annual Data Report 2003
14. Muruve NA, Shoskes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005; 80: 709-716
15. Martis G, Diana M, Ombres M et al. Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience. J Surg Oncol 2007; 95: 513-518
16. Ward JF, ZinckeH, Bergstralh EJet al. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 2004; 172: 1328-1332
17. Thomas AA, Nguyen MM, Gill IS. Laparoscopic transperitoneal radical prostatectomy in renal transplant recipients: a review of three cases. Urology 2008; 71: 205-208
18. Robert G, Elkentaoui H, Pasticier G et al. Laparoscopic radical prostatectomy in renal transplant recipients. Urology 2009; 74: 683-687
19. Paiva CS, Andreoni C, Cunha GPet al. Differences among patients undergoing perineal or retropubic radical prostatectomy in pain and peri-operative variables: a prospective study. BJU Int 2009; 104: 1219-1226
20. Antonopoulos IM, Nahas WC, Piovesan AC et al. Radical retropubic prostatectomy for localized prostate cancer in renal transplant patients. Urology 2008; 72: 1362-1365
21. Mouzin M, Bachaud JM, Kamar N et al. Three-dimensional confor-mal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation 2004; 78: 1496-1500
22. Ojo A, Wolfe RA, Agodoa LY et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66: 1651-1659
23. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
24. Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93
25. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997; 2: 14-17
26. Zhang W, Zhu J, Efferson CL et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-defi-cient mouse model of prostate cancer. Cancer Res 2009; 69: 7466-7472
27. Wang Y, Mikhailova M, Bose S et al. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008; 27: 7106-7117
28. Cinar B, De Benedetti A, Freeman MR. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 2005; 65: 2547-2553
29. Kauffman HM, Cherikh WS, Cheng Yet al. Maintenance immunosup-pression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
30. Sharef S, Jac J, Khan M et al. Rapamycin for androgen-independent prostate cancer (AIPC). J Clin Oncol 2006; 24: 14584
31. Figlin RA, Brown E, Armstrong AJ et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008; 6: S1-S20